Product Search

#18501 Anti-Human TPO Rabbit IgG Affinity Purify

Intended Use：
Research reagents
Application：
WB, IHC
Package Size1：
100 μg
Package Size2：
25 μg
Note on Application Abbreviations
WB:Western Blotting
IHC:Immunohistochemistry

※ The product indicated as "Research reagents" in the column Intended Use cannot be used
　 for diagnostic nor any medical purpose.
※ The datasheet listed on this page is sample only. Please refer to the datasheet
　 enclosed in the product purchased before use.

Product Overview

Product Overview

Product Code 18501
Product Name Anti-Human TPO Rabbit IgG Affinity Purify
Intended Use Research reagents
Application WB, IHC
Species Human
Immunizing antigen Synthetic peptide of the N terminal part of HumanThrombopoietin
Purification Method Purified with antigen peptide
Specificity Not cross-react with human EPO and human G-CSF.
Package Form Lyophilized product from 1 % BSA in PBS containing 0.05% NaN3
Storage Condition 2 - 8℃
Poisonous and Deleterious Substances Applicable
Cartagena Not Applicable
Package Size 1 100 μg
Package Size 2 25 μg
Remarks1 The commercial use of products without our permission is prohibited. Please make sure to contact us and obtain permission.

Product Description

Product Description

Thrombopoietin (TPO) is produced primarily in the liver and secondarily in the kidneys and bone marrow. It can bind to a receptor (which is the proto-oncogene c-Mpl, a homolog of an envelope protein of the myeloproliferative leukemia virus) on primitive blood cells and megakaryoctes and stimulate those cells to grow (proliferate) and evolve into platelet-producing megakaryocytes. The mass of TPO predicted from the sequence is about 35 kDa, but masses reported from measurements of material in serum or in culture fluid from recombinant cells vary from 18-70 kDa. This has led to suggestions that TPO is highly glycosylated and that it is susceptible to proteolytic processing. In clinical trails, TPO has proven useful in shortening the time for platelet recovery after chemotherapy but it is not currently approved for routine use. It is quite clear, however, that TPO does not regulate the release of platelets by megakaryocytes. This final step in platelet formation seems to be regulated by a separate process.
Contact Us >